Human EPO Platinum ELISA (short incubation)

Description: The human Erythropoietin ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human Erythropoietin.

Cell culture supernatant, serum and plasma (EDTA, citrate, heparin), were tested with this assay.

Erythropoietin (EPO) is a hormone produced by the kidney that promotes the formation of red blood cells in the bone marrow. EPO is a glycoprotein with a molecular weight of 34 kDa. The kidney cells that primarily make EPO are specialized and sensitive to low oxygen levels in the blood. These cells release EPO when the oxygen level is low in the kidney.
EPO binds the Epo receptor (Epo R) on erythroid progenitors in bone marrow eliciting proliferation, maturation, and differentiation of red blood cells thereby increase the oxygen-carrying capacity of the blood.
EPO is the prime physiological regulator of red blood cell production.

The measurement of EPO in the blood is useful in the study of bone marrow disorders and kidney disease. Elevated levels of EPO can be seen in polycythemia, a disorder in which there is an excess of red blood cells. Lower than normal levels of EPO are seen in chronic renal failure.
EPO plays an important role in the brain's response to neuronal injury. EPO is also involved in the wound healing process. Measurement of serum immunoreactive erythropoietin has shown that overproduction of EPO can be an adaptive response to conditions producing tissue hypoxia, such as smoking chronic obstructive pulmonary disease, renal hypoxia or cyanotic heart disease. Elevated serum levels have further been found in patients suffering from various neoplastic diseases, such as renal carcinomas and benign renal tumors, liver carcinomas and hepatomas, cerebellar hemangioblastomas and other neoplastic disorders. Serum levels of EPO lower than normal are found in various forms of anemias. In case EPO is not primarily involved in the cause of the anemia, elevated levels of EPO are found in serum of the patients suffering from diseases like aplastic anemias, iron deficiency, megaloblastic anemias, thalassemias and myelodysplastic syndromes.

References: Gore,C.J.; Clark,S.A.; Saunders,P.U.. Nonhematological mechanisms of improved sea-level performance after hypoxic exposure. Med.Sci.Sports Exerc. 2007;39:1600-1609. (Link)

Vychytil,A.; Haag-Weber,M.. Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int Suppl 1999;69:S71-S78. (Link)

Faris,P.M.; Ritter,M.A.. Epoetin alfa. A bloodless approach for the treatment of perioperative anemia. Clin Orthop.Relat Res 1998;60-67. (Link)

Mocini,D.; Leone,T.; Tubaro,M.; Santini,M.; Penco,M.. Structure, production and function of erythropoietin: implications for therapeutical use in cardiovascular disease. Curr.Med.Chem. 2007;14:2278-2287. (Link)

Manegold,C.. The causes and prognostic significance of low hemoglobin levels in tumor patients. Strahlenther.Onkol. 1998;174 Suppl :17-19. (Link)

Mittelman,M.. Anemia of cancer: pathogenesis and treatment with recombinant erythropoietin. Isr.J.Med.Sci. 1996;32:1201-1206. (Link)

Mossuz,P.. Influence of the assays of endogenous colony formation and serum erythropoietin on the diagnosis of polycythemia vera and essential thrombocythemia. Semin.Thromb.Hemost. 2006;32:246-250. (Link)

Silverberg,D.S.; Wexler,D.; Iaina,A.; Schwartz,D.. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin.Nephrol. 2006;26:296-306. (Link)

Ludwig,H.; Pohl,G.; Osterborg,A.. Anemia in multiple myeloma. Clin.Adv.Hematol.Oncol. 2004;2:233-241. (Link)

Jelkmann,W.. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998;18:555-559. (Link)

Spivak,J.L.. Serum immunoreactive erythropoietin in health and disease. J Perinat Med. 1995;23:13-17. (Link)

De Los Santos,J.F.; Thomas,G.M.. Anemia correction in malignancy management: threat or opportunity?. Gynecol.Oncol. 2007;105:517-529. (Link)

Michiels,J.J.; Bernema,Z.; Van,Bockstaele D.; De,Raeve H.; Schroyens,W.. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF). Pathol.Biol.(Paris) 2007;55:92-104. (Link)